Immunotherapy is changing the paradigm of multiple myeloma (MM) management and
daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for …

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains
significant, highlighting the need for new effective strategies. In recent years, daratumumab …

Checkpoint inhibitors (CI) instigate anticancer immunity in many neoplastic diseases, albeit
only in a fraction of patients. The clinical success of cyclophosphamide (C)-based …

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality
remains high, emphasizing the need for more effective therapies. Daratumumab, a fully …

Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of
all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal …

Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …

In the primary analysis of LYRA, daratumumab+ cyclophosphamide/bortezomib/
dexamethasone (DARA+ CyBorD) was effective and well tolerated in newly diagnosed …

The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma
for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory …

Simple Summary A common characteristic of multiple myeloma (MM) is the dysfunction of
patients' immune system, a condition termed immunosuppression. This state is mainly due to …

Approval of daratumumab (DARA), an IgGk1 monoclonal antibody targeting CD38, for the
treatment of relapsed/refractory multiple myeloma as monotherapy in November 2015 …